The use of indirect treatment comparisons (ITCs) has increased significantly in recent years, particularly in the assessment of oncology and rare diseases where direct head-to-head trials may be impractical or unavailable, with numerous oncology and orphan drug submissions incorporating ITCs to support regulatory decisions and health technology assessment (HTA) recommendations.
The Value & Evidence team at EVERSANA (Krista Tantakoun, Christopher Olsen, Fatemeh Mirzayeh Fashami, Imtiaz Samjoo and Chris Cameron), in collaboration with Dr. Brian Hutton, professors at Kyoto University and Yokohama City University School of Medicine in Japan, and colleagues at Janssen Pharmaceutical, critically reviewed and synthesized assessment documents for oncology drug submissions that included ITCs from various regulatory bodies and HTA agencies around the world. This comprehensive literature review highlights the global acceptance and contribution of ITCs to oncology reimbursement recommendations and pricing decisions made by varying authorities with diverse assessment frameworks across North America, Europe, and the Asia-Pacific region.
This work underscores the critical role and widespread application of ITCs in supporting healthcare decision-making worldwide, which can contribute to bolstering the credibility and recognition of ITCs across decision-making bodies of diverse regions and assessment frameworks. The increasing incorporation of ITCs in drug submissions and evaluations is expected to enhance the expertise of authorities globally in considering and accepting such data.
For a deeper understanding, check out the Advances in Therapy article here.
Author
As an Associate Manager on the Value & Evidence team at EVERSANA™, Krista contributes to evidence synthesis projects that support global HEOR initiatives. Since joining the team in 2020, Krista has been involved in…
Christopher is a Research Assistant II in the Evidence Synthesis group at EVERSANA. Christopher has been with EVERSANA since 2021 where he has supported systematic and targeted literature reviews across a variety of disease areas including prostate…
Fatemeh is a Research Associate in the Value & Evidence Division at EVERSANA, with experience in evidence synthesis, value communications, and economic modelling. Fatemeh holds an MSc in Health Research Methodology in the HTA…
As Senior Director of the Value & Evidence team at EVERSANA, Imtiaz leads evidence synthesis projects that support global HEOR initiatives involving systematic literature reviews, indirect treatment comparisons, and health economic modeling, to support reimbursement…
Dr. Chris Cameron is a global thought leader in health economics and outcomes research with over a decade of experience. Prior to joining EVERSANA, Chris was a partner at Cornerstone Research Group Inc., and…